Preliminary Trial of SNA014 for Pancreatic Cancer
Recruiting · NCT07597772 · Interventional (participants receive a specific treatment) · Lead sponsor: SmartNuclide Biopharma
View the official record on ClinicalTrials.gov →Interventions studied
68Ga-NODAGA-SNA006
What this trial is about
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Early Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Aged between 18 and 75 years (inclusive);
- Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
- Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
- Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
- Pathology test results from within the past year;
Exclusion criteria
- Patients with other clearly diagnosed malignant tumours;
- Patients with uncontrolled severe infections, or those with other serious comorbidities;
- Patients with a life expectancy of ≤3 months;
- Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
- Patients deemed unsuitable for participation in this study by the investigator.
Where it is running
1 location listed.
- Tianjin Medical University Cancer Institute and Hospital - Tianjin, Tianjin Municipality, China